- Home
- CLVT vs HAE Comparison
CLVT vs HAE Comparison
Compare CLVT & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLVT
- HAE
- Stock Information
- Founded
- CLVT 2016
- HAE 1971
- Country
- CLVT United Kingdom
- HAE United States
- Employees
- CLVT N/A
- HAE N/A
- Industry
- CLVT EDP Services
- HAE Medical/Dental Instruments
- Sector
- CLVT Technology
- HAE Health Care
- Exchange
- CLVT Nasdaq
- HAE Nasdaq
- Market Cap
- CLVT 2.8B
- HAE 3.3B
- IPO Year
- CLVT N/A
- HAE 1991
- Fundamental
- Price
- CLVT $4.29
- HAE $52.21
- Analyst Decision
- CLVT Hold
- HAE Buy
- Analyst Count
- CLVT 5
- HAE 10
- Target Price
- CLVT $4.83
- HAE $84.20
- AVG Volume (30 Days)
- CLVT 3.8M
- HAE 945.0K
- Earning Date
- CLVT 11-05-2025
- HAE 11-06-2025
- Dividend Yield
- CLVT N/A
- HAE N/A
- EPS Growth
- CLVT N/A
- HAE 46.89
- EPS
- CLVT N/A
- HAE 3.28
- Revenue
- CLVT $2,500,300,000.00
- HAE $1,346,046,000.00
- Revenue This Year
- CLVT N/A
- HAE N/A
- Revenue Next Year
- CLVT N/A
- HAE $6.50
- P/E Ratio
- CLVT N/A
- HAE $15.93
- Revenue Growth
- CLVT N/A
- HAE 0.91
- 52 Week Low
- CLVT $3.04
- HAE $50.68
- 52 Week High
- CLVT $7.15
- HAE $94.99
- Technical
- Relative Strength Index (RSI)
- CLVT 49.62
- HAE 30.00
- Support Level
- CLVT $4.11
- HAE $53.10
- Resistance Level
- CLVT $4.54
- HAE $54.52
- Average True Range (ATR)
- CLVT 0.14
- HAE 1.22
- MACD
- CLVT -0.01
- HAE 0.53
- Stochastic Oscillator
- CLVT 40.70
- HAE 7.61
About CLVT Clarivate Plc
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas while Europe, Middle East, and Africa account for around a quarter.
About HAE Haemonetics Corporation
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.